Clinical impact of recently detected susceptibility genes for schizophrenia by Maier, Wolfgang et al.
ll common diseases in the general population
are strongly influenced by genetic factors.This is also
true for schizophrenia.A long series of family,twin,and
adoption studies has clearly demonstrated that heri-
tability is the strongest determinant of schizophrenia.
Variance-analysis estimates in twin samples allocate
about 80% of the total etiological variance to genetic
factors. The underlying genetic mechanism (as evi-
denced from family and twin data) is clearly not
Mendelian;the complexity of patterns of familial aggre-
gation can best be explained by the operation of multi-
ple genes, each with a modest or small effect, and by
additional impact of nongenetic, environmental forces.
Thus,causal genes are extremely unlikely to explain the
vast majority of cases;instead,genes influencing the risk
of developing schizophrenia (susceptibility genes) play
the major role.Similarly to other common diseases such
as hypertension or diabetes, the search for susceptibil-
ity genes contributing by DNA-sequence variation to
schizophrenia has turned out to be difficult, and the
time taken to obtain the first replicable hints was two
decades.
Breakthrough in the search for 
susceptibility genes
In the last 2 years we have experienced a period of
excitement in the genetics of schizophrenia, after
decades of frustration. Claims of the involvement of
genes in the manifestation of schizophrenia were put
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After years of frustration, the search for genes impacting
on schizophrenia is now undergoing some exciting devel-
opments. Several proposals of susceptibility genes have
been able to be supported by replications. Thus, there are
now at least three very strong candidates: the gene for
dysbindin (DTNBP1), the gene for neuregulin-1 (NRG1),
and a less well-understood gene locus, G72/G30, which are
likely to influence manifestations of schizophrenia. Other
“hot” candidates such as the disrupted-in-schizophrenia
1 gene (DISC1) and the gene coding for protein kinase B
(AKT1) might also prove to be susceptibility genes in the
next future. The clinical implications of these findings are
not yet fully visible. However, some first insights are pos-
sible: most of the genetic findings lack diagnostic speci-
ficity, and are also reproduced in bipolar disorder. Strong
associations are also obtained on a symptomatic level, not
only on a diagnostic level. The pathophysiological role of
these hot candidate genes is currently under intensive
study.      
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possible through a genome-wide,hypothesis-free search
for genes predisposing to schizophrenia.The successful
strategy encompassed two steps:(i) mapping of genes in
broad candidate areas on the genome by linkage analy-
sis; (ii) identification of susceptibility genes within this
region by either systematic narrowing down or trial and
error.
Following this strategy, three genes emerged as strong
candidates for susceptibility genes: the dysbindin gene
on chromosome 6p (DTNBP1),
1,2 the neuregulin-1 gene
on chromosome 8p (NRG1),
3 and an up-to-now
unknown gene locus on chromosome 13q, only
expressed in humans (G72/G30).
4 Remarkably,for each
of these genes a majority of studies have reported sig-
nificant associations with markers and/or marker com-
binations (haplotypes). However, the associated mark-
ers and haplotypes vary across studies for all three
genes.
Caveats to current claims for susceptibility genes for
schizophrenia
The confidence in these three claims is,however,limited
for the following reasons:
•The fact that the reported at-risk haplotypes in the dif-
ferent studies/samples are not overlapping,and do not
include a common denominator allele or core haplo-
type for any of the claimed susceptibility genes.
• Poor reproducibility of the identical at-risk haplotype
in different samples, although for each of the claimed
susceptibility genes the vast majority of published
inquiries found alleles and haplotypes.
•Absence of demonstrated function of any of the
extracted at-risk haplotypes.
• No expressed exonic DNA-sequence variants can
explain the reported associations, ie, neither of these
claimed susceptibility genes contains DNA-sequence
variants that might:
• result in change of the amino-acid sequence in
the expressed protein;
• account for any of the reported genetic associ-
ations with schizophrenia.
•The failure to identify one or more susceptibility vari-
ants in any of the claimed susceptibility genes directly
influencing the etiology of schizophrenia.
Thus, there is a set of consistencies and inconsistencies
which are difficult to understand in combination.
What is the meaning of these findings? 
Given the variation of associated markers/haplotypes
across studies and small relative risks,the reported find-
ings might reflect false-positives.This possibility, how-
ever,is very unlikely.For example,let us look at NRG1:
The proportion of reports with significant associations
in a 300 kb region around the exon 1 is too high to be
due to chance (12 out of 14).In addition,the strong asso-
ciation of the originally identified at-risk haplotypes was
independently replicated, and several subsequent stud-
ies did not use this marker combination; furthermore,
this lack of association of original haplotypes occurred
in Asian populations, due to its very low frequency,
whereas more common variants at the same loci were
associated with schizophrenia.
5
Taking the findings for all the abovementioned genes
together,a general pattern can be recognized:
• Several genes impact on the manifestation of schizo-
phrenia; causal genes can be excluded; the absence of
strong linkages to any locus across all genome-wide
linkage scans.
•All susceptibility genes only contribute by a small or,
maximally,moderate effect;the relative risks are small
in outbred populations (OR 1.5-2.5).
•The mode of interaction between genes coding for
schizophrenia remains obscure.
•The mutants directly influencing the risk of schizo-
phrenia are difficult to find, and still have to be iden-
tified; mutations in expressed components (exons) of
the genes causing a change in the amino-acid sequence
of the protein have not been identified up to now.
Instead, several studies report a differential gene
expression in cases versus controls in target areas of
the brain for NRG1 and DTNBP1; given that associ-
ated alleles/haplotypes are located in introns,it can be
suggested that the pathogenic mutations induce a reg-
ulatory dysfunction.
The meaning of the variation of haplotypes across stud-
ies is currently not appropriately understood.Two puta-
tive interpretations are possible:
• Different “causal” mutations in the same gene con-
tribute to the emergence of schizophrenia;these muta-
tions are not yet known; different “causal” mutations
might predominate in different samples due to
“genetic heterogeneity” of schizophrenia; significant
associations to different haplotypes may be a conse-
quence.
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variable across populations and samples;thus,the posi-
tional markers in linkage disequilibrium with the same
“causal”mutations are different between populations
and samples.
It is currently not possible to decide which of both
options is true.In any case,it is very unlikely that the dis-
parity between associated haplotypes of the gene
reflects a “false positive”finding.
Alternative, successful strategies
Two alternative strategies have also turned out to be suc-
cessful:
• Cytogenic analyses in isolated families highly loaded with
schizophrenia:A translocation was detected to cosegre-
gate with the condition status in the family.
6A specific
gene (not previously known) on chromosome 1 was reg-
ularly disrupted, and was named DISC1. Surprisingly,
common mutations in this gene were also found to be
associated with schizophrenia in outbred populations.
7
• Gene expression might guide to susceptibility genes:
Given the plethora of differentially expressed genes in
postmortem brains of patients with schizophrenia,spe-
cific hypotheses are required to sharpen the focus to
differentially expressed genes for further study.
Assuming that synaptic and postsynaptic transmission
is a crucial feature of schizophrenia, phosphokinases
present as a family of candidate proteins;polymorphic
genes coding for these units of intracellular signal
transmission thus became “hot”candidate genes.These
DNA-sequence variants in the differentially expressed
protein kinase B (AKT1) were found to be associated
with schizophrenia.
8 Several replications of the origi-
nal finding have now been published.
9
The detected susceptibility genes throw light on the eti-
ology and the pathophysiology of schizophrenia. None
of the abovementioned detected candidate genes has
been implicated in the development of schizophrenia
before.Therefore,unraveling their role in the core can-
didate processes underlying schizophrenia, brain matu-
ration, and signal transduction has been the subject of
extensive study in the last 2 to 3 years,in in-vitro,animal,
and postmortem studies. In addition, the clinical corre-
lates of at-risk haplotypes of the putative susceptibility
genes,ie,diagnoses,psychopathological features,course,
and neurobiological correlates of schizophrenia, might
elucidate the underlying disease process.
Functional and clinical implications
In the absence of the “causal”mutations influencing the
etiology and pathogenesis of schizophrenia, conclusive
functional and clinical implications can not yet be iden-
tified.However,there are emerging patterns:
Diagnostic specificity of claimed susceptibility genes?
Recent cross-nosological twin studies propose sharing
of predisposing genetic factors between schizophrenia
and bipolar disorder.
10 This observation motivated the
test for associations of at-risk haplotypes and at-risk alle-
les for schizophrenia in bipolar disorder, too: the
G72/G30 gene
11,12 and the NRG1 gene
13 were also found
to be implicated in the etiology of bipolar disorder.
Associations between bipolar disorder and variants of
the dysbindin gene had not been reported up to now.
14
Are converging results in favor of a common predispos-
ing susceptibility allele? To answer this question,associ-
ations with the same haplotype/marker in schizophrenia
and in bipolar disorder in the same population are
required.And,indeed,Schumacher et al
12 were able to
support this possibility for the G72/G30 gene,and Green
et al
13 for the NRG1 gene. A similar (diagnostically
unspecific) pattern is emerging for DISC1.
6A conclusive
answer to the question of diagnostic specificity,however,
is only possible if the same pathogenic variant impacts in
the same direction on the risk for each of both disorders.
Are the two disorders contributing to the observed
associations in a global manner or through a specific
symptom or symptom pattern? 
A refined analysis proposed persecutory delusions to
explain the association between the G72/G30 haplotype
and bipolar disorder. This finding was replicated in an
independent sample.
15The association with the neuregulin-
1 gene is also largely due to specific symptoms in bipolar
cases:mood-incongruent psychotic features proposing a
specific effect in this subset of functional psychosis.
13Thus,
the question remains:what is the most appropriate clini-
cal target for an involved susceptibility allele or haplotype?
Core symptoms,or diagnoses which are defined through
symptom patterns and additional criteria?
It should be kept in mind that complex behaviors such
as psychotic and affective disorders are influenced by
multiple genes, with each of them influencing multiple
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tions.Against this background it is remarkable that all
risk genes identified for schizophrenia and bipolar dis-
order are involved in glutamatergic transmission
16 or in
the development of neurons and glial cells.These obser-
vations point to cross-diagnostic communalities in glu-
tamatergic transmission and neurodevelopment.
The impact of individual genetic contributions 
operates at the level of specific symptoms/symptom
patterns but less so on diagnoses
Symptom-based genetic association studies had been–up
to now–only rarely conducted for recently proposed sus-
ceptibility genes for schizophrenia. Thus, it has been
demonstrated that the DTNBP1 at-risk haplotype is
preferentially associated with negative symptoms.
17
Another example is G72/G30:the association of the at-
risk haplotype with bipolar disorder is exclusively medi-
ated by the symptom “persecutory delusion.”
15
Genetic modification of neurobiological features of
schizophrenia might occur independently of the
genetic influence on vulnerability
Given the limited empirical work on the recently pro-
posed susceptibility genes for schizophrenia,conclusive
evidence is not available. Based on the spatial expres-
sion pattern of NRG1, DTNBP1, and G72/G30 and
interacting genes,an influence on synaptic transmission
as a common biochemical pathway has been proposed.
18
Although this hypothesis is attractive given the impact
of glutamate on schizophrenia and its treatment, direct
genetic evidence is missing.However,the clinical or neu-
robiological phenotype can also be modulated by poly-
morphic genes which do not contribute to the vulnera-
bility to the disorder (so-called modulator gene).
19 An
extensively studied example of this kind is the catechol-
O-methyltransferase (COMT) gene.A series of studies
reported that the Val/Met polymorphism modifies neu-
robiological functions associated with schizophrenia as
working memory or information processing: the Val-
variant being associated with less achievement. On the
other hand the Val-variant of the COMT gene is not
associated with schizophrenia, as evidenced by the
recent meta-analysis.
20
The long-term impact of susceptibility genes of 
schizophrenia on treatment will be the detection of
new targets for new therapeutic agents
Susceptibility genes are beginning to be pinpointed in
new circuits involved in the pathophysiology of schizo-
phrenia.
18 The next step will be to uncover the interac-
tions and mechanisms of risk enhancement for schizo-
phrenia. Animal models can be established for this
purpose using transgenic techniques.The modification
of involved circuits and networks by a variety of drugs
can be tested by these means.The pharmaceutical dis-
covery mechanism might help to optimize this process.
Appropriate drugs will then hopefully result for use in
human drug trials,aiming at a more causal treatment of
schizophrenia than is currently available.This hypothe-
sis, however, is under discussion.
21 More refined analy-
ses are needed for each of these genes to uncover their
true role in mediating the risk for schizophrenia.
Summary
A series of discoveries has strongly promoted the field
of neurobiology of schizophrenia. Several very strong
claims for susceptibility genes for schizophrenia are now
under ongoing investigation.Although these claims are
partly replicable, a series of inconsistencies remains.
Despite these still-to-be-resolved issues, the clinical
implications are already visible. Currently, the major
conclusions are,(i) that most of the claimed susceptibil-
ity genes for schizophrenia also reveal genetic associa-
tions with bipolar disorder, probably even through the
same at-risk haplotypes; thus, a shared genetic vulnera-
bility to both disorders becomes an emerging scenario;
(ii) although diagnoses are useful to detect susceptibil-
ity genes,the genotype-phenotype relationship might be
more symptom- than diagnosis-based. ❏
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Repercusión clínica de los genes 
recientemente detectados que confieren
susceptibilidad frente a la esquizofrenia
Después de años de frustración, el estudio de los
genes que influyen en la esquizofrenia está dando
por fin sus frutos. Se han confirmado algunas pro-
puestas de los genes que confieren susceptibilidad.
Así, hoy conocemos como mínimo tres aspirantes
sólidos: el gen de la disbindina (DTNBP1), el gen de
la neuregulina-1 (NRG1) y un locus génico menos
conocido, G72/G30 parecen influir en las manifesta-
ciones de la esquizofrenia. Otros aspirantes “serios,”
como el gen DISC1 (disrupted in schizophrenia 1) y
el gen cifrador de la proteincinasa B (AKT1), podrían
convertirse en genes de susceptibilidad en un futuro
próximo. Aún no están claras las implicaciones clíni-
cas de estos datos pero cabe augurar algunas pros-
pecciones iniciales: la mayoría de los datos genéticos
carece de especificidad diagnóstica y se reproduce
también en el trastorno bipolar. Asimismo, se obser-
van asociaciones fuertes en un plano sintomático, no
sólo diagnóstico. En estos momentos se examina con
intensidad la utilidad fisiopatológica de estos genes,
firmes aspirantes. 
Impact clinique des gènes de susceptibilité
détectés récemment dans la schizophrénie
Après des années de recherche sans résultat
concluante, le domaine de recherche génetique dans
la schizophrénie est entré aujourd'hui dans une
phase passionnante. La réplication des résultats de
plusieurs  études a permis d'étayer l'importance
potentielle de gènes de susceptibilité proposés.
Actuellement, au moins trois gènes sont considérés
comme candidats très sérieux: le gène dysbindin
(DTNBP1), le gène neuroregulin-1 (NRG1) et un locus
moins bien caractérisé, le G72/G30, qui sont proba-
blement impliqués dans la pathogenèse de la schi-
zophrénie D'autres candidats tels que le "disrupted
in schizophrenia 1 gene" (DISC 1), et l'AKT1, codant
pour la protéine kinase B, pourraient s'avérer des
gènes de susceptibilité dans un futur proche. Les
implications cliniques de ces résultats ne sont cepen-
dant pas encore clairement établis. Quelques conclu-
sions préliminaires peuvent être tirées: la plupart des
résultats ne sont pas spécifiques pour la schizophré-
nie et se retrouvent également dans les trouble bipo-
laires. Des associations existent aussi bien au niveau
diagnostique que symptomatique. Le rôle physiopa-
thologique de ces gènes candidats est actuellement
en cours d'études approfondies.
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